Resource Entry form

Resource Details

TitleA DNA vaccine against tuberculosis based on the 65 kDa heat-shock protein differentially activates human macrophages and dendritic cells.
Linkhttp://www.gvt-journal.com/content/pdf/1479-0556-6-3.pdf
Attached Resource
Full text (for search)
Author(s)Franco LH; Wowk PF; Silva CL; Trombone AP; Coelho-Castelo AA; Oliver C; Jamur MC; Moretto EL; Bonato VL.
AbstractBACKGROUND: A number of reports have demonstrated that rodents immunized with DNA vaccines can produce antibodies and cellular immune responses presenting a long-lasting protective immunity. These findings have attracted considerable interest in the field of DNA vaccination. We have previously described the prophylactic and therapeutic effects of a DNA vaccine encoding the Mycobacterium leprae 65 kDa heat shock protein (DNA-HSP65) in a murine model of tuberculosis. As DNA vaccines are often less effective in humans, we aimed to find out how the DNA-HSP65 stimulates human immune responses.

Methods: To address this question, we analysed the activation of both human macrophages and dendritic cells (DCs) cultured with DNA-HSP65. Then, these cells stimulated with the DNA vaccine were evaluated regarding the expression of surface markers, cytokine production and microbicidal activity.

Results: It was observed that DCs and macrophages presented different ability to uptake DNA vaccine. Under DNA stimulation, macrophages, characterized as CD11b+/CD86+/HLA-DR+, produced high levels of TNF-alpha, IL-6 (pro-inflammatory cytokines), and IL-10 (anti-inflammatory cytokine). Besides, they also presented a microbicidal activity higher than that observed in DCs after infection with M. tuberculosis. On the other hand, DCs, characterized as CD11c+/CD86+/CD123-/BDCA-4+/IFN-alpha-, produced high levels of IL-12 and low levels of TNF-alpha, IL-6 and IL-10. Finally, the DNA-HSP65 vaccine was able to induce proliferation of peripheral blood lymphocytes.

Conclusions: Our data suggest that the immune response is differently activated by the DNA-HSP65 vaccine in humans. These findings provide important clues to the design of new strategies for using DNA vaccines in human immunotherapy.
Peer Reviewer
PublisherBioMed Central
SourceGenetic Vaccines and Therapy
Publication TypeResearch study
CategoryInvestigation, Prevention
Level of EvidenceEvidence cited
CoverageNational
FormatPdf
LanguageEnglish
Access RightsFree
Date of publishing01/21/2008
Date of last review by us03/06/2008

(Adding a Reviewer's Assessment requires User Authentication)


N.B Submitted documents do not go online immediately.
They are approved by our content managers before being posted on the NeLI/NRIC web sites


All Reviews:

No documents found